Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M, Landgren O, Raje N, Niesvizky R, Bensinger WI, Berdeja JG, Kovacsovics T, Vesole DH, Fang B, Kimball AS, Siegel DS. Alsina M, et al. Among authors: kimball as. Am J Hematol. 2021 Feb 1;96(2):226-233. doi: 10.1002/ajh.26041. Epub 2020 Dec 15. Am J Hematol. 2021. PMID: 33125764 Free PMC article. Clinical Trial.
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M. Orlowski RZ, et al. Among authors: kimball as. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. doi: 10.1016/j.clml.2019.04.018. Epub 2019 May 2. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31160237 Free article. Clinical Trial.
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2).
Boccia RV, Bessudo A, Agajanian R, Conkling P, Harb W, Yang H, Pinchasik D, Kimball AS, Berenson JR. Boccia RV, et al. Among authors: kimball as. Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):433-437. doi: 10.1016/j.clml.2017.05.009. Epub 2017 May 10. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28576443 Free article. Clinical Trial.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Dimopoulos MA, et al. Among authors: kimball as. Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28843768 Clinical Trial.
47 results